Molecular Partners (MOLN) has released an update.
Molecular Partners AG, in collaboration with Orano Med, has reported promising preclinical results for MP0712, their Radio-DARPin therapy targeting DLL3, which showed favorable tumor targeting, antitumor activity, and safety profiles. The candidate is designed for the treatment of small-cell lung cancer and other neuroendocrine tumors, with a first-in-human study expected to begin in 2025. These findings bolster the potential of MP0712 to address the high unmet need in aggressive cancer forms, leveraging Molecular Partners’ expertise in DARPin therapeutics.
For further insights into MOLN stock, check out TipRanks’ Stock Analysis page.
